|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.245 USD | +6.40% |
|
-16.85% | -3.65% |
| 06-17 | GSK says US FDA approves urinary tract infection treatment Utebzi | AN |
| 06-17 | GSK plc Receives US FDA Approval for Oral Antibiotic Tebipenem for Complicated Urinary Tract Infections | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Neutral |
| Resistance | 2.54 | 2.54 | 2.85 |
| Spread/Res. | -13.19% | -13.19% | -22.63% |
| Spread/Supp. | +17.29% | +17.29% | +17.91% |
| Support | 1.88 | 1.88 | 1.87 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- SPRO Stock
- Charts Spero Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
